Century Therapeutics, Inc. (IPSC)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Century Therapeutics: A Biotech With Interesting Optionality Opportunities
Century Therapeutics earns a speculative Buy rating, with a 10-15% upside and right-skewed return potential for risk-tolerant investors. IPSC pivoted from oncology to autoimmune CAR cells and CNTY-813 for Type 1 diabetes, now the pipeline's main value driver. Recent management actions reduced quarterly cash burn from $35M to $20M, extending runway to Q1 2028 after a 134% dilutive PIPE.
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to Q1 2029 and a recent $135M PIPE from major biotech funds, IPSC is well-capitalized to advance its T1DM program toward IND submission in 2026 and initial clinical data in 2027.
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Century Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 5.96M | $5.94M | $13.42M | $7.48M | 126.03% |
| NM Nir Messafi Deep Track Capita LLP | 9.49M | $21.44M | $21.35M | -$94,877.45 | -0.44% |
| GS George Song Superstring Capital Management LP | 119,308 | $120,501.18 | $268,443 | $147,941.82 | 122.77% |
| SAM Smartleaf Asset Management LLC Smartleaf Asset Management LLC | 1 | $1 | $2.25 | $1.25 | 125% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 1,064 | $594.36 | $2,394 | $1,799.64 | 302.79% |
Century Therapeutics, Inc. (IPSC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Century Therapeutics, Inc. ever had a stock split?
Century Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brent Pfeiffenberger CEO | NASDAQ (NGS) Exchange | 15673T100 CUSIP |
| US Country | 140 Employees | - Last Dividend | - Last Split | 18 Jun 2021 IPO Date |
Overview
Century Therapeutics, Inc. represents an innovative force in the biotechnology sphere, primarily focusing on the development of advanced genetically engineered allogeneic cell therapies aimed at combatting both solid tumors and hematological malignancies. Established in 2018 and based in Philadelphia, Pennsylvania, the company distinguishes itself through its commitment to leveraging cutting-edge scientific advancements to address some of the most challenging cancers. Furthermore, Century Therapeutics has entered into a notable strategic collaboration with Bristol-Myers Squibb Company, embarking on joint efforts to develop and market up to four groundbreaking immune effector cell (iNK or iT) programs tailored to combat acute myeloid leukemia and multiple myeloma among other malignancies.
Products and Services
- CNTY-101
- CNTY-102
- CNTY-107
- Strategic Collaboration with Bristol-Myers Squibb
A pioneering therapeutic candidate from Century Therapeutics, CNTY-101 is an allogeneic, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) integrated natural killer (iNK) cell therapy. Currently in Phase 1 clinical trials, this state-of-the-art treatment targets CD19 for patients experiencing relapsed, refractory B-cell lymphoma, showcasing the company’s commitment to advancing cancer treatment modalities through innovative cellular engineering.
This bi-specific CD19 + CD22 CAR-iT (immune T cell) product candidate aims to provide a novel therapeutic option for individuals with relapsed, refractory B-cell lymphoma and other B-cell malignancies. Through its dual-targeting mechanism, CNTY-102 represents Century Therapeutics’ endeavor to enhance the efficacy of cancer immunotherapy by addressing tumor escape pathways.
CNTY-107 is a Nectin-4 CAR-iT (immune T cell) targeted product candidate developed for the treatment of Nectin-4 positive solid tumors. By focusing on Nectin-4, a protein frequently overexpressed in various solid tumors, this therapeutic candidate exemplifies Century Therapeutics' innovative approach to extending the benefits of CAR-T cell therapy beyond hematological cancers to solid tumors.
Century Therapeutics has fortified its product development strategy through a strategic collaboration with Bristol-Myers Squibb Company. This partnership encompasses the development and commercialization of up to four iNK or iT programs, including CNTY-104, targeted at acute myeloid leukemia, and CNTY-106, aimed at addressing multiple myeloma. These collaboration programs embody a significant extension of Century Therapeutics’ therapeutic ambitions, leveraging mutual strengths to advance cancer treatment.
